Merus NV to Present and Poster on MCLA-128 and MCLA-129 Programs - Corporate Call Transcript
Thank you, Jimmy. With me on the call today is Ton Logtenberg, our President, Chief Executive and Principal Financial Officer; and Dr. Andres Sirulnik, our chief medical officer.
Yesterday, we issued a press release that you can find on our website at merus.nl, which includes certain updates regarding the company. Further, slides are available for download on today's call and available in the Investor section of merus.com -- merus.nl.
Before we get started on this call, we will also make certain forward-looking statements within the meaning of the Private Securities Litigation Reformat of 1995. This may include statements about our future expectations and plans and events and circumstances that has not yet occurred including but not limited to projections about Merus' operating activities for 2019 and beyond, clinical and regulatory anticipated milestones, the treatment potential for our Biclonics candidates, and the development plans for our compound and for our collaboration partners.
These forward-looking statements are based on the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |